EARLY: A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicentre Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects who are Asymptomatic At Risk for Developing Alzheimer’s Dementia.
DEMENTIA TRIALS AUSTRALIA